Genitourinary Cancer—Prostate, Testicular, and Penile
Cora N. Sternberg, Karim Fizazi, Fred Saad, et al.
The abstract concludes:
ENZA treatment resulted in a statistically significant 27% reduced risk of death compared with PBO, demonstrating that initiation of ENZA + ADT before the onset of detectable metastasis improves OS in men with CRPC and rapidly rising PSA. This OS benefit ensues despite crossover from the PBO arm to ENZA and higher rates of subsequent antineoplastic therapies in men from the PBO arm. Safety was consistent with previous clinical trials. This final OS analysis from PROSPER provides prospective validation of MFS as a potential surrogate endpoint for OS in nmCRPC and supports the continued use of ENZA + ADT as a standard of care in men with nmCRPC and rapidly rising PSA. Clinical trial information: NCT02003924.
Published simultaneously on NEJM:
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
K. Shitara and Others
Neal D. Shore, Daniel J. George, Fred Saad,et al.
The abstract concludes:
Relugolix achieved castration as early as Day 4 and demonstrated superiority over leuprolide in sustained T suppression through 48 weeks, faster T recovery after discontinuation and a 50% reduction in MACE. Relugolix has the potential to become a new standard for T suppression for patients with advanced prostate cancer. Clinical trial information: NCT03085095.
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
N.D. Shore and Others
Fred Saad, Guilhem Roubaud, Giuseppe Procopio, et al.
The abstract concludes:
Olaparib reduced the burden of pain and time to first opiate use in pts with mCRPC and HRR gene alterations vs pcNHA, demonstrating a clinical and symptomatic patient benefit. Clinical trial information: NCT02987543.
Simultaneously published in the NEJM:
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Johann de Bono, Joaquin Mateo, Karim Fizazi, et al.
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Genitourinary (Abstracts #5500, 5501, 5503)
Access Content Now